600557 Stock Overview Researches and develops, produces, and sells Chinese medicines. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Jiangsu Kanion Pharmaceutical Co.,Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Jiangsu Kanion PharmaceuticalLtd Historical stock prices Current Share Price CN¥14.12 52 Week High CN¥24.09 52 Week Low CN¥11.77 Beta 0.46 1 Month Change -1.67% 3 Month Change -1.19% 1 Year Change -31.19% 3 Year Change 15.36% 5 Year Change -4.01% Change since IPO -34.58%
Recent News & Updates
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2025 Dec 27
New minor risk - Earnings quality Nov 13
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million. Nov 08
Investor sentiment improves as stock rises 15% Nov 08
Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023) Oct 31
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30 See more updates
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2025 Dec 27
New minor risk - Earnings quality Nov 13
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million. Nov 08
Investor sentiment improves as stock rises 15% Nov 08
Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023) Oct 31
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30
Investor sentiment improves as stock rises 17% Sep 28
Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023) Jul 27
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024 Jun 28
First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023) Apr 14
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024 Mar 29
Investor sentiment improves as stock rises 18% Mar 17
Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024 Mar 11
Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022) Mar 11
Now 20% undervalued after recent price drop Feb 28 Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares. Feb 09
Investor sentiment deteriorates as stock falls 17% Feb 02
Now 23% undervalued after recent price drop Jan 31
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024 Dec 29
New minor risk - Share price stability Nov 30
Now 20% undervalued Nov 28
Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022) Oct 26
Investor sentiment deteriorates as stock falls 17% Oct 20
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Investor sentiment improves as stock rises 19% Sep 28
Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022) Jul 13
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023 Jun 27
Less than half of directors are independent May 19
First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022) Apr 08
Investor sentiment improves as stock rises 17% Mar 31
Investor sentiment improves as stock rises 16% Mar 15
Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021) Feb 21
Investor sentiment improves as stock rises 18% Feb 16
Investor sentiment deteriorated over the past week Dec 19
Less than half of directors are independent Nov 16
Now 21% undervalued Oct 26
Investor sentiment improved over the past week Oct 16
Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021) Oct 10
Less than half of directors are independent Apr 27
First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021) Apr 13
Investor sentiment improved over the past week Apr 12
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 05
Investor sentiment improved over the past week Mar 01
Investor sentiment improved over the past week Jan 12
Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020) Aug 20
First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020) Apr 30
Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019) Apr 11
Investor sentiment improved over the past week Feb 23
New 90-day low: CN¥9.43 Jan 22
New 90-day low: CN¥10.99 Dec 24
New 90-day low: CN¥12.14 Dec 08
Third quarter earnings released Oct 28
New 90-day low: CN¥12.29 Sep 24
New 90-day low - CN¥12.67 Sep 09
New 90-day low - CN¥12.93 Aug 24
First half earnings released Aug 04
Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020 Jul 08 Shareholder Returns 600557 CN Pharmaceuticals CN Market 7D -1.5% -1.9% -0.6% 1Y -31.2% -5.7% 8.3%
See full shareholder returns
Return vs Market: 600557 underperformed the CN Market which returned 9.2% over the past year.
Price Volatility Is 600557's price volatile compared to industry and market? 600557 volatility 600557 Average Weekly Movement 6.0% Pharmaceuticals Industry Average Movement 7.3% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.9% 10% least volatile stocks in CN Market 5.6%
Stable Share Price: 600557 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600557's weekly volatility (6%) has been stable over the past year.
About the Company Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others.
Show more Jiangsu Kanion Pharmaceutical Co.,Ltd. Fundamentals Summary How do Jiangsu Kanion PharmaceuticalLtd's earnings and revenue compare to its market cap? 600557 fundamental statistics Market cap CN¥8.04b Earnings (TTM ) CN¥544.35m Revenue (TTM ) CN¥4.48b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 600557 income statement (TTM ) Revenue CN¥4.48b Cost of Revenue CN¥1.14b Gross Profit CN¥3.34b Other Expenses CN¥2.80b Earnings CN¥544.35m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 30, 2025
Earnings per share (EPS) 0.96 Gross Margin 74.61% Net Profit Margin 12.15% Debt/Equity Ratio 0.04%
How did 600557 perform over the long term?
See historical performance and comparison Dividends
2.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 10:12 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Jiangsu Kanion Pharmaceutical Co.,Ltd. is covered by 30 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Zhi Xue Diao Avic Securities Co., Ltd Changming He BOCI Research Ltd. Feifei Ma Bohai Securities Co., Ltd.
Show 27 more analysts 
